Search

Background: In Canada, more than 2 million people live with osteoporosis, a disease that increases the risk for fractures, which result in excess mortality and morbidity, decreased quality of life and loss of autonomy. This guideline update is intended to assist Canadian health care professionals in the delivery of care to optimize skeletal health and prevent fractures in postmenopausal females and in males aged 50 years and older. Methods: This guideline is an update of the 2010 Osteoporosis Canada clinical practice guideline on the diagnosis and management of osteoporosis in Canada. We followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework and quality assurance as per Appraisal of Guidelines for Research and Evaluation (AGREE II) quality and reporting standards. Primary care physicians and patient partners were represented at all levels of the guideline committees and groups, and participated throughout the entire process to ensure relevance to target users. The process for managing competing interests was developed before and continued throughout the guideline development, informed by the Guideline International Network principles. We considered benefits and harms, patient values and preferences, resources, equity, acceptability and feasibility when developing recommendations; the strength of each recommendation was assigned according to the GRADE framework. Recommendations: The 25 recommendations and 10 good practice statements are grouped under the sections of exercise, nutrition, fracture risk assessment and treatment initiation, pharmacologic interventions, duration and sequence of therapy, and monitoring. The management of osteoporosis should be guided by the patient's risk of fracture, based on clinical assessment and using a validated fracture risk assessment tool. Exercise, nutrition and pharmacotherapy are key elements of the management strategy for fracture prevention and should be individualized. Interpretation: The aim of this guideline is to empower health care professionals and patients to have meaningful discussions on the importance of skeletal health and fracture risk throughout older adulthood. Identification and appropriate management of skeletal fragility can reduce fractures, and preserve mobility, autonomy and quality of life., Fracture risk increases with advancing age, as a result of declining skeletal strength and increased risk of falling. In Canada, more than 2 million people live with osteoporosis. (1) Every [...]

Thousand Oaks-based pharma giant Amgen Inc. closed a pair of multibillion-dollar deals last year, both aimed at furthering its ability to treat autoimmune and inflammatory diseases. The bigger of the [...]

Biotechnology company Capsida Biotherapeutics opened its gene therapy manufacturing facility in Thousand Oaks just two years after the company's founding. The 15,000-square-foot facility cuts out the manufacturing middleman for Capsida [...]

About Kevin Sharer KEVIN SHARER WAS elected Amgen's CEO in May 2000. He is Amgen's third CEO and became the company's third chairman of the board in January 2001. Sharer […]

Although the U.S. military's recent downsizing hurt financial profits at many businesses catering to service personnel, financial services provider USAA sailed through the period with its customary double-digit growth. Ignoring [...]

Amgen Inc's stock prices declined 37% in 1993 even though the company's 1993 cash flow exceeded what most biotech companies earn during their entire existence. The company's management, plans and financial potential is examined.

Amgen, the world's largest independent biotechnology company, was founded in Thousand Oaks, California in 1980 as AMGen (Applied Molecular Genetics). More than twenty years later, Amgen's aspiration to be the [...]

Fake cancer treatment throws industry a scare In May of this year, drug maker Amgen Inc. sent a letter to health-care professionals warning them about fake Neupogen, its infection-fighting drug [...]

THERE'S a new buzz in local biotech circles about Amgen Inc., the granddaddy of West Coast biotech outfits. The shoptalk: New management and a maturing emphasis on the bottom line [...]

Biotech leaders Amgen and Biogen seek to replenish maturing pipelines. As some of the key products among the biotech companies face increased competition and slowing sales, the leading biotech companies [...]

A MGEN Inc. may be the world's premier biotech company, but to the dismay of many in the L.A. biotech community it has yet to become the same type of [...]

Los Angeles is home to a number of world-class biotech research centers. Here are some of the biggest and best. Amgen Inc. 1 Amgen Center Drive, Thousand Oaks Amgen, with [...]

Every year, the Business Journal compiles a list of L.A. County's 100 largest public companies. And every year, there are fewer Fortune 500 companies on it. Currently, there are 17 [...]

How Gordon Binder keeps Amgen healthy. FOR A MAN WHO HAS PILOTED THE WORLD'S LARGEST AND most successful independent biotechnology company through its most dynamic period to date, Amgen Inc. […]

With the creation of the San Diego-based Amgen Ventures capital fund, biotechnology powerhouse Amgen Inc. recently jumped on the bandwagon of other drug makers hoping to supplement their pipeline of [...]